PubMed Health⌕ Search

Biomedical subjects

V V Kukharchuk

Publications and source records attributed to V V Kukharchuk.

At least 19 recordsLinked to original sources
PubMed1992

[Use of immunosorption for selective decrease of lipoprotein (A) levels in patients with coronary atherosclerosis].

Lipoprotein (a) [L(a)] is an atherogenic lipoprotein, its human plasma concentration correlates with the occurrence of coronary heart disease. The procedure for selectively removing L(a) with an anti-L(a) immunosorbent was performed to treat 3 patients who had high L(a), normal total cholesterol and other lipoprotein levels. All the patients had coronary stenosis as documented by angiography. After L(a)-apheresis, the level of L(a) decreased by 72%, while that of other plasma components, including low density lipoproteins virtually unchanged. Thus, the procedure of L(a)-apheresis is an effective and safe method for lowering human blood L(a) concentrations. In addition, this in vivo model allows information on L(a) metabolism to be obtained.

Adult↗
PubMed1992

[Changes in plasma lipid and apoprotein levels in patients with ischemic heart disease after hemosorption].

All the patients who had undergone a course of non-specific hemosorption (HS) for clinical indications showed lower plasma lipid levels and largely lower triglyceride concentrations. The patients with hypercholesterolemia alone simultaneously displayed decreased levels of cholesterol, high density lipoproteins, and apoprotein A-I. Apoprotein B levels reduced in patients having normal lipid values and in those with isolated hypercholesterolemia. The changes in the levels of lipids and apoproteins were different for 2 weeks after hemosorption in relation to the baseline lipid spectrum. The patients with coronary heart disease with hyperlipidemias had positive trends in lipid spectral changes: the parameters of atherogenic classes of lipids tended to decrease, whereas those of antiatherogenic lipid classes tended to show a slight increase. There was a negative direction in the dynamics of the studied parameters in renal patients, in those who had normal baseline lipid values, and in those with isolated hypo-alpha-cholesterolemia, i. e. higher plasma cholesterol and triglyceride, low density lipoprotein cholesterol and apoprotein B levels.

Adult↗
PubMed1991

LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II.

LDL induced a reversible increase in [Ca2+]i in platelets of healthy subjects and FH-patients. In both groups the effects of LDL were potentiated 2.3-fold by epinephrine. [Ca2+]i increases, induced by LDL, ADP and PAF were more prominent in platelets of FH-patients. This may explain the platelet hyperaggregability in such conditions.

Adenosine Diphosphate↗
PubMed1991

[Changes of blood antioxidative enzyme activity and lipid levels in patients with coronary atherosclerosis treated with probucol].

The paper provides the results of 3-month probucol (lipomal) treatment of patients with coronary heart disease concurrent with Types 2a and 2b hyperlipidemia. There were 20% and 17% decreases in total cholesterol and low density lipoprotein cholesterol levels, respectively. The drug failed to affect the levels of high density lipoprotein cholesterol and triglycerides. Having antioxidative properties, probucol significantly enhances the activity of the antioxidative enzymes superoxide dismutase and glutathione peroxidase, which controls the efficacy of coronary heart disease patients with hyperlipidemia.

Coronary Artery Disease↗
PubMed1991

[The dynamics of the concentrations of immunoglobulins and circulating immune complexes during low-density lipoprotein apheresis in patients with hereditary hypercholesterolemia].

Sessions of-low density lipoproteins (LDL) apheresis using sorbents with mono- and polyclonal antibodies possessing the most selective and specific effect with respect to LDL provoked a less marked decrease of the concentrations of immunoglobulins and circulating immune complexes. This attests to their high selectivity and specificity. Sorbents with dextran sulfate and heparin sepharose exerted a more evident influence on the concentrations of these serum components. However, that was not accompanied by any clinical manifestations of immune deficiency. The use of plasmapheresis brought about a more pronounced lowering of the concentrations of the serum components under study.

Adolescent↗
PubMed1991

[The plasmoimmunosorption of low-density lipoproteins in the treatment of patients with hereditary hypercholesterolemia].

The authors describe the experience gained with the use of apheresis of low density lipoproteins with the aid of the Soviet immunosorption columns with polyclonal and monoclonal antibodies in patients with hereditary hypercholesterolemia resistant to the diet and hypolipidemic drug therapy. High specificity of apheresis of low density lipoproteins and high efficacy of the use of the sorption columns to correct hypercholesterolemia have been demonstrated.

Adolescent↗
PubMed1991

[The use of plasmapheresis in the combined treatment of patients with unstable stenocardia].

Plasmapheresis (PA) was provided to 82 patients with unstable angina pectoris refractory to drug treatment. PA did not influence blood osmolarity, acid-base equilibrium or blood electrolyte level. The patients manifested a slight rise of hematocrit and a decrease of plasma oncotic pressure. PA gave rise to a significant lowering of blood viscosity, a reduction of blood fibrinogen, total protein, cholesterol and triglycerides. Clinically, there was a marked decline of the frequency of angina pectoris of rest and effort attacks. The doses of antianginal drugs could be reduced. PA brought about a significant rise of the count of rosette-forming cells. The increase of drug sensitivity induced by PA sessions correlated with the clinical efficacy of the treatment. Later on the antianginal effect was attained with far lower drug doses.

Adult↗
PubMed1990

Apheresis of low density lipoproteins using a heparin-based sorbent with low antithrombin III binding capacity.

A sorbent based on heparin fraction with low affinity for antithrombin III is proposed for low density lipoproteins apheresis in hypercholesterolemia. Heparin was fractionated on antithrombin III-Sepharose; fractions with high and low affinity for antithrombin III were immobilized on CNBr-activated Sepharose 4B. Both sorbents appeared to have an LDL-binding capacity essentially similar to that of the sorbent based on unfractionated heparin. However only plasmasorption on a low affinity heparin-containing sorbent did not reduce plasma antithrombin III. Hence the use of this sorbent may be advantageous over the currently applied sorbents with unfractionated heparin in the treatment of familial hypercholesterolemia.

Absorption↗
PubMed1990

Heparin-sorbent for low density lipoproteins removal in hypercholesterolemia.

Heparin-sorbent was developed in the USSR Cardiology Research Center for LDL-apheresis in patients with familial hypercholesterolemia. Clinical trials of the sorbent were started in 1985. Heparin-sorbent has a high capacity for LDL. One column (400ml) can remove 3 - 6g of LDL cholesterol, depending on the initial LDL content in the plasma. The sorbent demonstrates a high stability, it can withstand more then 75 sorbtion-desorbtion cycles with only a slight loss of the initial capacity. It means that one column can work for 1,5-2,0 years when used weekly. Heparin-sorbent is the sorbent of limited selectivity, apo-B content in eluate is 40-60% of the total protein content, but it is important that it does not bind HDL.

Binding Sites↗
PubMed1990

[Effect of bezamidine on plasma cholesterol and triglyceride levels in patients with familial hyperlipoproteinemia].

The hypolipidemic agent bezamidine, a fibroic acid derivative (KPKA, Yugoslavia), was applied to treat Types 2a, 2b, 4 and 5 familial hyperlipoproteinemias. The highest reduction in plasma cholesterol and triglyceride concentrations was found in patients with Types 2b, 4 and 5 familial hyperlipoproteinemias. No clear-cut adverse effects of the drug were found during 3 months.

Adolescent↗
PubMed1990

[The effect of hemosorption on the indices of the structural-functional status of the erythrocyte membranes in arterial hypertension patients].

A study was made of the stability of the parameters of 2 membranous tests, used in the differential diagnosis of some forms of arterial hypertension, under the influence of hemoperfusion, an extracorporeal treatment method. One of these tests consists in the measurement of the Na-Li countertransport velocity across the erythrocytic membrane. It allows revealing functional disorders in ion transport across the cellular membranes. The second one involves the determination of monoclonal antibody (mon Ab) binding to the fragmented erythrocytic membranes. The test enables recording the structural changes that occur in the erythrocytic membranes. Before and after hemoperfusion the velocity of Na-Li countertransport was measured in 8 patients suffering from arterial hypertension whereas mon Ab binding to the fragmented erythrocytic membranes in 6 patients. After hemoperfusion all the patients manifested an increase of the velocity of Na-Li countertransport (by 15 to 108% as compared to the initial). On the other hand, after that procedure the patients with arterial hypertension did not demonstrate any appreciable alterations in mon Ab binding to the fragmented erythrocytic membranes. Thus, the membranous test (mon Ab binding to the fragmented erythrocytic membranes) reflecting the structural characteristics of the erythrocytic membrane appears more "rigid" and stable as compared to Na-Li countertransport reflecting the functional properties of the erythrocytic membrane, which, as it was to be expected, respond more readily to different external effects.

Antibodies, Monoclonal↗
PubMed1990

[The effect of plasmapheresis and the plasmasorption and immunosorption of low-density lipoproteins on the humoral immunity function of patients with hereditary hypercholesterolemia].

It has been shown that prolonged use of plasmapheresis with a 7-day interval in patients with hereditary hypercholesterolemia is potentially dangerous because of possible development of immunodeficiency. LDL plasmasorption and immunosorption produce a beneficial effect on the concentration of immunoglobulins. It is assumed that immunosorption permits the elimination not only of lipoproteins but also lipoprotein-containing immune complexes from the blood channel.

Adolescent↗
PubMed1989

Effect of plasmapheresis on the liver uptake of ApoB-lipoproteins labeled with technetium-99m.

To study liver low density lipoprotein (LDL)-receptor activity before and after plasmapheresis, [99mTc] very low density lipoprotein (VLDL) was used. Autologous VLDL was labeled, sterilized by filtration, and administered intravenously to patients under a gamma camera. The uptake of lipoproteins in the liver was measured by scintiscanning. Liver activity curves were generated for each patient. The liver activity in patients with the heterozygous form of familial hypercholesterolemia (FH) and in patients with symptomatic atherosclerosis (SA) without hereditary deficit of LDL receptors was reduced as compared to healthy people. Plasmapheresis enhanced the liver uptake of the 99mTc-labeled lipoproteins in atherosclerotic patients. Thus, labeled metabolites could presumably be of use in assessing the effect of plasmapheresis on liver function.

Adult↗